Immunovant COO sells shares to cover RSU taxes

Immunovant, Inc. Chief Operating Officer Gloria Melanie reported two open-market sales totaling 2,036 shares of common stock on July 8, 2026.

Rhea-AI Filing Summary

Immunovant, Inc. Chief Operating Officer Gloria Melanie reported two open-market sales totaling 2,036 shares of common stock on July 8, 2026. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the July 1, 2026 vesting and settlement of previously granted restricted stock units, under a mandated “sell to cover” arrangement rather than a discretionary trade.

Insider Trade Summary

Net Seller: 2,036 shares

Net Sell 2 txns

Insider Gloria Melanie

Role Chief Operating Officer

Sold 2,036 shs ($81K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	1,930	$39.53	$76K
Sale	Common Stock F1, F3	106	$39.99	$4K

Holdings After Transaction: Common Stock — 222,357 shares (Direct)

Footnotes (3)

1. F1. On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
3. F3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Key Figures

Total shares sold: 2,036 shares First transaction weighted average price: $39.53 per share Second transaction weighted average price: $39.99 per share +4 more

7 metrics

Total shares sold 2,036 shares Open-market sales on July 8, 2026 to cover tax withholding

First transaction weighted average price $39.53 per share Common stock sale of 1,930 shares

Second transaction weighted average price $39.99 per share Common stock sale of 106 shares

RSU grant size 76,181 RSUs Restricted stock units granted on April 1, 2025

RSUs vested 4,761 RSUs Portion of the grant that vested on July 1, 2026

First sale price range $38.91–$39.89 per share Multiple executions aggregated into a weighted average price

Second sale price range $39.92–$40.03 per share Multiple executions aggregated into a weighted average price

Key Terms

restricted stock units ("RSUs"), sell to cover, weighted average price, tax withholding obligations

4 terms

restricted stock units ("RSUs") financial

"the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

sell to cover financial

"tax withholding obligations to be funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immunovant (IMVT) COO Gloria Melanie report in this Form 4?

Immunovant (IMVT) COO Gloria Melanie reported selling 2,036 shares of common stock on July 8, 2026. The transactions were open-market sales executed to cover tax withholding obligations from vested RSUs.

How many Immunovant (IMVT) shares did the COO sell and at what prices?

The COO sold 2,036 shares of Immunovant common stock in two trades at weighted average prices of about $39.53 and $39.99 per share. Each sale consisted of multiple executions within specified price ranges.

Why were the Immunovant (IMVT) shares sold by the COO?

The shares were sold to cover tax withholding obligations from the vesting and settlement of RSUs granted on April 1, 2025. The company required a “sell to cover” method, so the sales were not discretionary trades by the COO.

What RSU grant is referenced in the Immunovant (IMVT) Form 4 filing?

The filing references a grant of 76,181 restricted stock units (RSUs) awarded on April 1, 2025. Of these, 4,761 RSUs vested on July 1, 2026, triggering the related tax-withholding share sales.

Were the Immunovant (IMVT) COO’s sales part of a trading plan?

The filing explains the sales were mandated as a “sell to cover” for tax withholding on vested RSUs. It characterizes them as non-discretionary, driven by the issuer’s election on how to satisfy tax obligations.

How were the sale prices determined in the Immunovant (IMVT) COO transactions?

Each transaction’s reported price is a weighted average price. The shares were sold in multiple executions within ranges of $38.91–$39.89 and $39.92–$40.03 per share, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gloria Melanie

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2026		S		1,930(1)	D	$39.53(2)	222,463	D
Common Stock	07/08/2026		S		106(1)	D	$39.99(3)	222,357	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Melanie Gloria	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)